Abstract: PROBLEM: To provide an anti-aging agent and a method for the anti-aging that are safe in long-term intake and ensures effective suppression of the progress of the aging. SOLUTION: Nicotinamide mononucleotide is contained as an active ingredient.

Abstract: A composition for use as a skin care formulation may include a combination of Vitamin C (L-ascorbic acid) and pentacyclic triterpene such as Asiatic Acid. A particular formulation may include by weight 5% to 25% Vitamin C (L-ascorbic acid); 0.005% to 2.0% of pentacyclic triterpene such as Asiatic Acid; 5% to 60% of a solvent comprising absolute, denatured alcohol; water. The composition may have a pH no more than about 3.0 and preferably no more than about 2.0. The multi-phase solution composition may also comprise Glutathione, Alpha-Arbutin, and Vitamin E and its derivatives.

Abstract: The present invention provides an eye make-up cosmetic composition comprising an acrylate-based copolymer, a preparation method therefor, and a cosmetic product using the same.

Abstract: The present invention relates to a process for treating keratin fibres, especially the hair, comprising the following steps: —application to the keratin fibres of a composition comprising one or more cationic acrylic copolymers comprising at least the units obtained from the following monomers: a) monomer derived from acrylic or methacrylic esters or amides and comprising at least one cationic group, and b) alkyl acrylate or methacrylate monomer, and—application of heat to the keratin fibres using a heating tool, the application of heat possibly taking place before, during or after the application of the composition, preferably during or after.

Abstract: The present invention relates to a composition comprising one or more vinylformamide/vinylamine copolymers, one or more fixing polymers other than vinylformamide/vinylamine copolymers, one or more nonionic surfactants chosen from oxyalkylenated, preferably oxyethylenated, fatty alcohols, and one or more cationic surfactants. The present invention also relates to a process for styling keratin fibres, comprising the application of this composition to said fibres, and also to the use of such a composition for shaping the hair.

Abstract: A powder for use in cosmetic and personal care products containing ultrafine polyhydroxyalkanoate (PHA), ultrafine polyhydroxybutyrate (PHB), or ultrafine polyhydroxybutyrate-co-hydroxyvalerate (PHBV).

Abstract: The present invention relates to a composition that is sprayable in mousse form comprising one or more vinylformamide/vinylamine copolymers, one or more nonionic surfactants chosen from oxyalkylenated, preferably oxyethylenated, fatty alcohols, and one or more propellants. The present invention also relates to a process for styling keratin fibres, comprising the application of this composition to said fibres, and also to the use of such a composition for shaping the hair.

Abstract: To provide an oily solid cosmetic having sufficient impact resistance and favorable use performance and use feeling (it is easy to scoop an appropriate amount by a finger and the cosmetic is easy to spread and has excellent tight adhesion, a makeup film with less pearl irregularity, and a moist finish) while the solid cosmetic can give sufficient elasticity feeling when touched by a finger. This oily solid cosmetic includes: a powder ingredient in an amount of 40 to 70 mass %, the powder ingredient containing sparkling powder; (A) silicone wax with a melting point of 25 to 55° C.; and (B) a crosslinked silicone elastomer.

Abstract: Disclosed is an unpigmented cosmetic composition for treatment of keratin materials, which includes at least one cosmetic butter and at least one styrenic film former. Also disclosed are methods of use for the unpigmented cosmetic composition, either as by itself, or as a primer for a pigmented cosmetic composition.

Abstract: The present disclosure is drawn to nail enamel compositions including cannabis sativa seed oil, and specifically to nail enamel compositions including a plasticizer, a solvent, a film forming polymer, and cannabis sativa seed oil. The plasticizer may be, e.g., a citric acid and/or benzoic acid derivative, and may be present in a total amount of between 1.0% and 10.0% by weight. The solvent may be, e.g., ethyl acetate, propyl acetate, butyl acetate, ethyl lactate, isopropanol, and/or propylene carbonate, and may be present in a total amount of at least 10%. The film forming polymer may include, e.g., a cellulose derivative and/or may include two or more polymers. The film forming polymer may be present in a total amount of between 5.0% and 70.0% by weight. The composition may include a colorant, such as a pigment, and the pigment may be present in an amount of at least 0.5% by weight.

Abstract: A composition is provided, wherein the composition includes an aqueous solvent, phenol, croton oil, and at least one saturated non-ionic ethoxylated fatty acid ester, and wherein the composition has a rate of separation of less than or equal to 0.5 mm/s. Another composition is also provided, wherein the composition includes an aqueous solvent, benzyl alcohol, ethylhexylglycerin, and at least one saturated non-ionic ethoxylated fatty acid ester. The compositions may be incorporated in to methods for treating skin conditions and cleansing skin, respectively.

Abstract: The present invention relates to an antioxidant, skin-whitening and wrinkle-reducing multifunctional cosmetic composition containing a fermented rice by-product extract or a fraction thereof as an active ingredient. By using a fermented rice by-product extract or a fraction thereof according to the present invention, the total phenolic content of a rice by-product can be increased by means of fermentation, extraction and fractionation, and a cosmetic composition showing high antioxidant capability and excellent skin-whitening and wrinkle-reducing effects can be provided.

Abstract: Disclosed is a method for preparing a low-molecular weight horse placenta enzyme hydrolysate. According to the present invention, through development of pretreatment and optimal enzymatic treatment, the horse placenta extract can be modified to a low-molecular weight. The low-molecular weight horse placenta hydrolysate obtained according to the present invention can exhibit excellent skin permeability due to low molecular weight.

Abstract: Colorant particles made from an insoluble protein-based substrate to which a dye is adsorbed are disclosed. The colorant particles are highly dispersible onto solid surfaces or within liquid systems, and thus can be used as substitutes for the alumina-based lake particles that are conventionally used as colorants in consumer products, such as food or beverage products, cosmetic products, pharmaceutical products, nutraceutical products, or toys.

Abstract: Multilayer dissolvable film suitable for oral administration, as well as method of use thereof and method of manufacturing thereof. The dissolvable film contains multiple (e.g., two or more) layers, configured such that the active ingredient(s) can be present in a total amount of at least about 30 wt. % (e.g., at least about 250 mg). The dissolvable film is mucoadhesive and capable of dissolving within about 60 seconds when placed in the oral cavity.

Abstract: The invention provides methods for enhancing the delivery of therapeutic compounds to the eye of a subject by administering plasmin or derivatives thereof and the therapeutic compounds to the eye.

Abstract: The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein—the composition comprises latanoprost and a liquid vehicle comprising a semifluorinated alkane; and—the composition is administered to the eye of a subject; and—the amount of latanoprost administered in a single dose per eye is in the range of from about 0.5 to 1.4 ?g.

Abstract: The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating. A second aspect of the present invention is a method of making a medical device that incorporates a drug in at least one coating. A third aspect of the present invention is a method of using a medical device of the present invention to treat, prevent from having, prevent from developing, control, reduce the severity, or reduce the progression of a disease, disorder or condition of a subject.

Abstract: The purpose of the present invention is to provide an intraoral retentive disintegrating solid preparation having excellent disintegrability and cohesiveness, a method for the production thereof, and a powder composition for use in the method for the said production. The present invention relates to an intraoral retentive disintegrating solid preparation comprising at least one kind of a disintegrator and at least one kind of a water-soluble polymer, wherein a disintegration starting time is within 40 seconds and a cohesiveness index is 0.4 or more, a method for the production thereof, and a powder composition for use in the method for the said production, etc.

Abstract: An aqueous solution of vitamin B12 can be stabilized by the synergistic effect of HPMC, carrageenan and potassium acetate. This property is used to develop four formulations—1. A solution used to prepare B12 loaded capsule shell matrix, 2. vitamin B12 injectable formulation, 3. vitamin B12 nasal formulation and 4. Vitamin B12 oral solution formulation.

Abstract: The invention relates to a product and process for sub-lingual delivery of cannabinoids. The product is a natural bubble gum much like old fashioned bubble gum. The sublingual delivery can aid in controlling dosage as well as the psychosomatic and physiological effects typical to a cannabis infused edible product.

Abstract: The present invention relates to gastroretentive formulations and to processes for preparation of the same. Particularly, the invention relates to gastroretentive dosage forms comprising at least one swelling agent and at least one swelling retardant.

Abstract: Aerosol formulations of ondansetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.

Abstract: The present invention provides a plasma aerosol inhalation device and a method for thinning the sputum. Various radicals generated by plasma can be inhaled in an aerosol form and delivered to the respiratory system for desired efficacy.

Abstract: Methods of the present disclosure utilize alcohol (e.g., ethanol) as an active ingredient or agent for disinfecting, washing, and/or treating infection in the upper and/or lower airways. Methods include aerosol inhalation, lung spraying, and/or lung lavage using ethanol-containing solutions. Such methods can be applied to complicated pneumonia and respiratory pandemics, including the COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Abstract: A single use packaged product including a tablet containing supplement powder with a density such that the tablet in will break apart to form a shake when submerged and manually shaken in a container of liquid. The packaged product also includes a package having a first portion and a second portion together defining a receiving area. The tablet is disposed inside of the receiving area, and enclosed by the package for protection from contamination and accidental exposure to moisture. The package is configured to expel the tablet via manual manipulation of the package.

Abstract: The present invention discloses a hydrogel that can be degraded under physiological conditions. The hydrogel includes at least one backbone moiety and an optional crosslinking moiety, and biodegradable linkers connecting backbone moieties and crosslinking moieties can be degraded by intramolecular cyclization.

Abstract: Liquid, gel, and semi-solid compositions containing naloxone base, or isomers or derivatives thereof, with one or more non-aqueous solvents, and optional viscosity adjusting agents, are provided. Methods of treating an individual exhibiting symptoms of respiratory depression associated with known or suspected opioid overdose including administering a liquid, gel, or semi-solid formulation containing a solution of naloxone base, or an isomer or a derivative thereof, in one or more non-aqueous solvents, are also provided.

Abstract: The disclosure provides stable formulations of cationic biocides that are primarily used in the treatment and prevention of infections. The disclosure is also concerned with processes for forming stable emulsions of cationic biocides and petrolatum.

Abstract: An improved method for the manufacture of an oil-in-water emulsion involves circulation of emulsion components between a first container and a second container via a homogenizer and/or via a microfluidization device. Usefully, all of the emulsion components from the first container are emptied before being returned.

Abstract: The invention relates to a nasally administrable composition comprising at least one active substance in magnesium-containing vesicular carrier, said carrier comprising glycol, phospholipids, water and at least one magnesium source. Methods for nasal administration of the composition, for example, for pain relief, are also provided.

Abstract: The present invention relates to a CD-RAP precursor protein comprising a pre-sequence and CD-RAP, and its use in manufacturing of native CD-RAP. The present invention further relates to a composition comprising CD-RAP and at least one positively charged amino acid and a buffer, pharmaceuticals comprising said composition, their use in methods of treating and/or preventing cartilage disease or injury in patients suffering from aggrecan degradation, and/or increased influx of water into the cartilage, and/or decreased CD-RAP expression, as well as methods of producing said composition and methods of storing CD-RAP in said composition. The present invention further relates to a composition comprising liposomes comprising encapsulated CD-RAP or a variant thereof, its use in methods of treating joint disease or injury, and methods of producing such liposomal composition as well as storing CD-RAP therein.

Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.

Abstract: Provided are methods for treating cancers and/or tumors in subjects. In some embodiments, the methods include administering to a subject an effective amount of a ceramide nanoliposome (CNL), wherein the CNL has a lipid bilayer that includes one or more C2-C24 ceramides and encapsulates one or more anti-cancer and/or anti-tumor agents. Also provided are methods for treating cancers and/or tumors associated with receptor tyrosine kinase or nuclear receptor activities, methods for treating Prostate Cancer, methods for inhibiting growth of EGFR-dependent cancers and/or tumors, methods for inhibiting growth of androgen receptor negative cells, method for reducing or eliminating androgen receptor negative cells from subject, CNLs that encapsulate one or more anti-cancer and/or anti-tumor agents, wherein the CNLs include a lipid bilayer that has one or more C2-C24 ceramides, and pharmaceutical compositions that include the disclosed CNLs.

Abstract: The invention relates to mRNA therapy for the treatment of Hemophilia A. mRNAs for use in the invention, when administered in vivo, encode Factor VIII, isoforms thereof, functional fragments thereof, and fusion proteins comprising Factor VIII. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of Factor VIII expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient Factor VII I activity in subjects.

Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions using solventless mixing methods. Excess coating material that is not bound to a coated API particle may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Specifically, a coating ratio and/or a dosing ratio can be used to minimize the residual amount of excess unbound coating material to minimize agglomeration of coating material during storage. In some embodiments, a pharmaceutical composition is provided, the pharmaceutical composition comprising: 65-85 % w/w API particles; 15-30 % w/w coating material coating the API particles; and 3-15 % w/w matrix surrounding the coated API particles, wherein the pharmaceutical composition comprises a disintegration time rate of less than 10 seconds for at least six months under storage conditions of at least 25° C. and at least 60 % relative humidity.

Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions that preserve the coating of coated API particles in a pharmaceutical suspension. Pharmaceutical compositions include coated active pharmaceutical ingredient (API) particles comprising: an API particle; a first coating comprising one or more deformed components coating the API particle; a second coating comprising silica surrounding and/or partially or fully embedded into the first coating, a matrix former, and a structure former.

Abstract: The present invention provides methods for preventing, inhibiting or treating a surgical site infection associated with a surgical operation comprising the step of applying to the surgical site a biocompatible, biodegradable substrate being impregnated and/or having its surface coated fully or partially with a matrix composition which provides local controlled and prolonged release of at least one pharmaceutically active agent at the surgical site.

Abstract: Tumors can be treated by introducing a first embolization agent (e.g., small embolic beads) into a blood vessel that supplies blood to the tumor, then introducing a therapeutic substance into the blood vessel at a position that is proximal with respect to the first embolization agent, and then introducing a second embolization agent (e.g., large embolic beads) into the blood vessel at a position that is proximal with respect to at least a portion of the therapeutic substance. The first embolization agent prevents complete systemic release of the substance, and the second embolization agent prevents retrograde washout of the substance. In some embodiments, the first embolization agent is omitted, and the second embolization agent impedes systemic release by impeding the forward flow of blood. In some embodiments, the therapeutic substance is an immunotherapy substance (e.g., CAR T-cells).

Abstract: The present invention relates to a film-coated tablet having a high chemical stability of an active ingredient, said film-coated tablet comprising: (a) a tablet core containing obeticholic acid or a pharmaceutically acceptable salt thereof; and (b) a coating layer, which is provided on the surface of the tablet core, containing a film base and being substantially free from any plasticizer or containing at least one kind of specific plasticizer.

Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.

Abstract: Solid oral dosage forms containing 325 mg of acetaminophen and 97.5 mg of ibuprofen or 500 mg of acetaminophen and 150 mg of ibuprofen, wherein the ibuprofen has a [D50] between 1 and 9 ?m, are described.

Abstract: The present invention relates generally to pharmaceutical formulations. Particularly, the present invention relates to a new delivery system for delivery of medical components to the lungs, and its utility in the fields of pharmaceutical formulation, drug delivery, medicine and diagnosis.

Abstract: The present invention relates to a method for preparing immediate and sustained release solid dosage forms, comprising antibodies and functional fragments thereof, by wet granulation, extrusion and spheronization,optionally coated with a delayed release coating the solid dosage forms prepared by the method and the use of the solid dosage forms in the topical treatment in the gastrointestinal tract of a patient.

Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions comprising Ibuprofen using solventless mixing methods. Excess coating material that is not bound to coated Ibuprofen may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Additionally, the compositions can be formulated to preserve the functional coating of coated Ibuprofen and to minimize aeration of Ibuprofen when mixed into suspension.

Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions that can minimize the aeration a pharmaceutical suspension during the production process. Pharmaceutical compositions include a plurality of API particles; a coating material encapsulating each API particle of the plurality of API particles; and a matrix solution/suspension comprising a matrix former, a structure former, and an anti-aerating agent.

Abstract: Disclosed herein are nanoparticles comprising a lipid core comprising a sterol; and a complex comprising a cationic agent and a therapeutic agent, wherein the complex is encapsulated within the lipid core. Methods to produce the nanoparticle comprise: combining a cationic agent, a therapeutic agent, and a first water-immiscible solvent with a first aqueous solution, thereby forming a mixture comprising a complex comprising the cationic agent and the therapeutic agent; combining the mixture with a second waterim-miscible solvent, thereby forming an aqueous phase and an organic phase, and separating the organic phase comprising the complex; combining the organic phase comprising the complex with a sterol and a first water-miscible organic solvent; and dispersing the complex in a second aqueous solution to form a herein disclosed nanoparticle. Methods for treating a disease and for reducing nanoparticle burst rate are also disclosed.

Abstract: Methods for encapsulating water-soluble biologic and small molecule active pharmaceutical ingredients (APIs) into nanoparticles by applying nanoprecipitation techniques and ion-pairing the nanoparticles with hydrophobic counterions to produce new API salts that exhibit altered solubilities are presented.

Abstract: In this specification, a pharmaceutical dosage form comprising a three-dimensional structural framework of thin, solid elements surrounded by interconnected void space is disclosed. The elements comprise at least a drug, a water-absorptive, polymeric excipient, and a hydrophilic surface composition. Upon immersion in a dissolution fluid the three-dimensional structural framework is wetted uniformly, transitions from solid to viscous due to the diffusion of dissolution fluid into the thin elements, expands in all dimensions, and disintegrates and releases drug. The disclosed dosage form enables greater drug delivery rates and better control of the drug concentration in blood for improving the efficacy and safety of drug therapies.

Abstract: A modular transdermal drug delivery system is provided, the system including: an upper module in which an outer backing layer is laminated to a pressure-sensitive adhesive layer that is covered by a removable release liner prior to assembly; and a lower module with a porous drug reservoir layer laminated to a skin-contact adhesive that affixes the system to the skin during drug delivery, where the skin-contact adhesive is, in one embodiment, an adhesive layer that is substantially co-extensive with the porous drug reservoir layer and, prior to use, protected with a second removable release liner. Methods of manufacture and use are also provided, as is an assembled transdermal drug delivery system fabricated by affixing the pressure-sensitive adhesive layer of the upper module to the porous drug reservoir layer of the lower module.